Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer

Investigational New Drugs

Volumn 15, Issue 4, 1997, Pages 361-364

  Sharma, Jivesh J ^a,b   Razvillas, Betty ^c   Stephens, C D ^c   Hilsenbeck, Susan G ^a   Sharma, Ashu ^a   Rothenberg, Mace L ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Texas Cancer Center   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Androgens; Clinical benefit; Flutamide; Pancreas cancer; Quality of life

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; FLUOROURACIL; FLUTAMIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; FEMALE; FLATULENCE; HUMAN; MALE; NAUSEA; NUTRITIONAL STATUS; ORAL DRUG ADMINISTRATION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031406518     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005989519350     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. Ca Cancer J Clin 47:5-27, 1997
2. Greenway B: Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J 283:751-753, 1981
3. Greenway B: Carcinoma of the exocrine pancreas: A sex hormone responsive tumor? Br J Surg 74:441-442, 1987
4. Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R: Androgen receptors in human normal and malignant pancreatic tissue and cell lines. Cancer 57:1992-1995, 1986
5. Diaz-Sanchez V, Morimoto S, Morales A, Robles-Diaz G, Cerbon M: Androgen receptors in the rat pancreas: Genetic expression and steroid regulation. Pancreas 11:241-245, 1995
6. Hayashi Y, Katayama H: Promoting effect of testosterone propionate on experimental exocrine pancreatic tumours by 4-hydroxy amino quinoline 1-oxide in rats. Toxic Lett 9:349-354, 1981
7. Greenway B, Duke D, Pym B, Iqbal MJ, Johnson PJ, Williams R: The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg 69:595-597, 1982
8. Kloppel G, Lohr M, Moesta, Bulow M: The effects of sex steroid hormones on pancreatic carcinoma grown in nude mice and tissue culture (Abstract). Dig Dis Sci 31:1137, 1986
9. Benz C, Hollander C, Miller B: Endocrine-responsive pancreatic carcinoma: Steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 46:2276-2281, 1986
10. Sumi C: Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in fischer rats treated with azaserine. Cancer Res 49:2332-2336, 1989
11. Sumi C: Inhibition of a transplantable pancreatic carcinoma by castration and estradiol administration in rats. Cancer Res 49:6687-6692, 1989
12. Rassmussen GH: Chemical control of androgen action. Ann Rep Med Chem 21:179-188, 1986
13. Gonzalez-Barcena D: Response to D-TRP-6 LHRH in advanced adenocarcinoma of the pancreas. Lancet ii:154, 1986
14. Kelsen DP, Portenoy RK, Thaler HT, Niedzwiecki D, Passik SD, Too Y, Banks W, Brennan MF, Foley KM: Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 13:748-755, 1995
15. Hickman DM, Miller RA, Rombeau JL, Twomey PL, Frey CF: Serum albumin and body weight as predictors of postoperative course in colorectal cancer. J Parenter Enteral Nutr 4:314-316, 1980
16. Klidjian AM: Relation of anthropometric and dynamometric variables to serious postoperative complications. Br Med J 281:899-901, 1980
17. Hunt D: Hand grip strength - a simple prognostic indicator in surgical patients. J Parenteral Enteral Nut 9:701-704, 1985
18. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 10:239-253, 1992
19. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo A-M, von Hoff DD: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Am Oncol 7:347-353, 1996
20. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Longnecker D: Hormones and pancreatic cancer. Int J Pancreatol 9:81-86, 1991
22. Zaniboni A, Meriggi F, Arcangeli G, Alghisi A, Huscher C, Marini G: Leuprolide and tamoxifen in the treatment of pancreatic cancer: A Phase II study. Eur J Cancer 30A:128, 1994
23. Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetto M, Martinoli C, Rollandi G, Marugo M, Fazzuoli L, Pugliese V: LH-RH analogue treatment in adenocarcinoma of the pancreas: A Phase II study. Oncology 50:77-80, 1993
24. Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J, Dowsett M, Harris AL: Hormonal treatment of pancreatic carcinoma: A Phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 67:379-382, 1993